Neurotransmitter systems via precursor supply

Neurotransmitter systems via precursor supply refers to a therapeutic strategy and physiological mechanism rather than a single molecular target like a receptor or enzyme. This approach is based on the principle that the synthesis of certain neurotransmitters, such as dopamine, serotonin, and acetylcholine, can be enhanced by increasing the concentration of their metabolic precursors in the brain [Source: PubMed, PMID: 6115404]. For example, Levodopa is administered to bypass the rate-limiting tyrosine hydroxylase step in dopamine synthesis to treat Parkinson's disease, while tryptophan or 5-HTP are used to boost serotonin levels [Source: NIH, 'Nutrients and Brain Function']. Because this term describes a broad pharmacological concept involving multiple transporters (e.g., SLC7A5) and enzymes (e.g., DDC), it is not classified as a discrete drug target in a structural sense. Instead, it represents a metabolic intervention aimed at restoring chemical balance in the central nervous system by saturating biosynthetic pathways.

Other names

Precursor loadingNeurotransmitter precursor therapySubstrate supplementation strategyPrecursor-mediated neurotransmitter modulation

The mechanism involves increasing the systemic and cerebral availability of rate-limiting metabolic substrates (precursors) which are then converted into active neurotransmitters by endogenous enzymes, such as aromatic L-amino acid decarboxylase (AADC) or choline acetyltransferase [Source: StatPearls, 'Physiology, Neurotransmitters'].